Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1
Frontiers in Microbiology · 04.08.2025 · 16
DOI: 10.3389/fmicb.2025.1631947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 04.08.2025. Verfasst von Isabel Zydek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisbu…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
COVID-19, caused by SARS-CoV-2, remains a global health challenge despite the availability of vaccines and antiviral treatments. The emergence of immune escape variants and the persistence of long COVID symptoms continue to complicate prevention and therapy, especially in low-resource settings. Functional inhibitors of acid sphingomyelinase (FIASMAs) have shown promise as broad-spectrum antiviral agents.
Methods
We evaluated the antiviral efficacy of amitriptyline, a widely used antidepressant and known FIASMA, against SARS-CoV-2. In vitro neutralization assays using pseudotyped virus-like particles (VLPs) and clinical isolates were performed to assess its ability to inhibit viral entry and replication.
Results
Amitriptyline significantly inhibited infection by SARS-CoV-2 VLPs bearing spike proteins, including those with mutations in the receptor-binding domain. Moreover, it reduced replication of clinical SARS-CoV-2 isolates D614G, Omicron BA.5, and Omicron XBB.1 in a dose-dependent manner at subtoxic concentrations.
Discussion
Our findings demonstrate that amitriptyline neutralizes SARS-CoV-2 across multiple variants. These results support the potential of amitriptyline as a repurposed antiviral drug. Further clinical studies are warranted to evaluate its efficacy and safety in treating COVID-19 in humans.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Department of Thoracic and Cardiovascular Surgery, West German Heart Center, University Hospital Essen, Essen, Germany.
Zitieren
APA
Zydek, I., Thümmler, L., Beckmann, N., Sehl, C., Soddemann, M., Grüneberg, R., Elsner, C., Kamler, M., Dittmer, U., Witzke, O., Kadow, S., Gulbins, E., Becker, K. A., & Krawczyk, A. (2025). Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1631947
Vancouver
Zydek I, Thümmler L, Beckmann N, Sehl C, Soddemann M, Grüneberg R, et al. Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1631947
BibTeX
@article{Zydek2025,
author = {Zydek, Isabel and Thümmler, Laura and Beckmann, Nadine and Sehl, Carolin and Soddemann, Matthias and Grüneberg, Rabea and Elsner, Carina and Kamler, Markus and Dittmer, Ulf and Witzke, Oliver and Kadow, Stephanie and Gulbins, Erich and Becker, Katrin Anne and Krawczyk, Adalbert},
title = {Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1631947}
}
EUVIMED